Healius Sells Lumus Imaging to Affinity Equity for $657 Million

Healius Ltd. agreed to sell its Lumus imaging unit to a private equity group for A$965 million ($657 million), as the loss-making Australian medical diagnostics company focuses on its pathology business.

The sale to Affinity Equity Partners represents a multiple of 25.4 times full-year earnings before interest and taxes, and will result in more than A$800 million in net proceeds after post-transaction adjustments and costs, Sydney-based Healius said in a statement Monday.

The owner of Agilex Biolabs, Dorevitch Pathology and IQ Pathology services reported net losses for the past two years. The sale, slated to close by March 2025, will ...